US5897992A
(en)
|
1996-09-27 |
1999-04-27 |
Cold Spring Harbor Laboratory |
Cell-free assay using oncogene-induced apoptosis in drug-resistant cells
|
US7807136B2
(en)
*
|
1997-01-13 |
2010-10-05 |
David S. Rose |
Method and composition for the treatment of cancer by the enzymatic conversion of soluble radioactive toxic precipitates in the cancer
|
US20030068382A1
(en)
*
|
1999-05-18 |
2003-04-10 |
Samuel Rose |
Method and composition for the treatment of cancer by the enzymatic conversion of soluble radioactive toxic agents into radioactive toxic precipitates in the cancer
|
US6555339B1
(en)
*
|
1997-04-14 |
2003-04-29 |
Arena Pharmaceuticals, Inc. |
Non-endogenous, constitutively activated human protein-coupled receptors
|
AU7966098A
(en)
|
1997-06-12 |
1998-12-30 |
Smithkline Beecham Corporation |
Hm74a receptor
|
US20040137563A9
(en)
*
|
1998-10-13 |
2004-07-15 |
Ruoping Chen |
Endogenous and non-endogenous versions of human G protein-coupled receptors
|
US20040117125A1
(en)
|
1999-04-26 |
2004-06-17 |
Hao Chen |
Drug discovery method and apparatus
|
US20020187514A1
(en)
|
1999-04-26 |
2002-12-12 |
Hao Chen |
Identification of molecular targets useful in treating substance abuse and addiction
|
WO2000065421A2
(en)
|
1999-04-26 |
2000-11-02 |
Novascreen Biosciences Corporation |
Receptor selectivity mapping
|
US6955873B1
(en)
|
2000-08-04 |
2005-10-18 |
Kenneth Blum |
Diagnosis and treatment system for reward deficiency syndrome (RDS) and related behaviors
|
AU782959B2
(en)
|
1999-11-17 |
2005-09-15 |
Arena Pharmaceuticals, Inc. |
Endogenous and non-endogenous versions of human G protein-coupled receptors
|
WO2001094385A2
(en)
|
2000-06-05 |
2001-12-13 |
Bayer Aktiengesellschaft |
Human hm74-like g protein coupled receptor
|
FR2814952B1
(en)
*
|
2000-10-06 |
2004-01-02 |
Flamel Tech Sa |
COLLOIDAL SUSPENSION OF SUBMICROMIC PARTICLES FOR VECTORIZATION OF ACTIVE INGREDIENTS AND THEIR METHOD OF PREPARATION
|
US6833447B1
(en)
*
|
2000-07-10 |
2004-12-21 |
Monsanto Technology, Llc |
Myxococcus xanthus genome sequences and uses thereof
|
US20030078218A1
(en)
*
|
2001-08-15 |
2003-04-24 |
Gabor Jarai |
Inflammation related G-protein coupled receptor
|
GB0021484D0
(en)
|
2000-09-01 |
2000-10-18 |
Boehringer Ingelheim Pharma |
Method for identifying substances which positively influence inflammatory conditions of chronic inflammatory airway diseases
|
WO2002061087A2
(en)
|
2000-12-19 |
2002-08-08 |
Lifespan Biosciences, Inc. |
Antigenic peptides, such as for g protein-coupled receptors (gpcrs), antibodies thereto, and systems for identifying such antigenic peptides
|
EP1366147A4
(en)
|
2001-03-07 |
2004-11-17 |
Bristol Myers Squibb Co |
Polynucleotide encoding a novel human g-protein coupled receptor, hgprbmy27
|
AU2002242910A1
(en)
|
2001-04-11 |
2002-10-28 |
Glaxo Group Limited |
Medicaments which are modulators of hm74 and/or hm74a activity
|
US20030143668A1
(en)
|
2001-06-18 |
2003-07-31 |
National Institute Of Advanced Industrial |
Guanosine triphosphate-binding protein coupled receptors
|
US20040076955A1
(en)
|
2001-07-03 |
2004-04-22 |
Eos Biotechnology, Inc. |
Methods of diagnosis of bladder cancer, compositions and methods of screening for modulators of bladder cancer
|
WO2003042661A2
(en)
|
2001-11-13 |
2003-05-22 |
Protein Design Labs, Inc. |
Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
|
US6902902B2
(en)
*
|
2001-11-27 |
2005-06-07 |
Arena Pharmaceuticals, Inc. |
Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders
|
US20040038201A1
(en)
|
2002-01-22 |
2004-02-26 |
Whitehead Institute For Biomedical Research |
Diagnostic and therapeutic applications for biomarkers of infection
|
EP1470420A4
(en)
|
2002-01-23 |
2005-08-24 |
Aventis Pharma Inc |
A nucleic acid encoding a g-protein-coupled receptor, and uses thereof
|
US20050118639A1
(en)
|
2002-02-22 |
2005-06-02 |
Takeda Chemical Industries, Ltd |
Method of determining ligand
|
JP2004049004A
(en)
|
2002-05-31 |
2004-02-19 |
Japan Science & Technology Corp |
5-oxo-ete receptor protein and its gene
|
JP2004065120A
(en)
|
2002-08-07 |
2004-03-04 |
Sumitomo Pharmaceut Co Ltd |
Marker for inflammatory bowel disease and use thereof
|
NZ538058A
(en)
|
2002-08-14 |
2006-11-30 |
Neurosearch As |
Quinuclidine derivatives and their use for treating disorders related to CNS and PNS
|
US20060134109A1
(en)
|
2002-09-09 |
2006-06-22 |
Nura Inc. |
G protein coupled receptors and uses thereof
|
US20050260639A1
(en)
*
|
2002-09-30 |
2005-11-24 |
Oncotherapy Science, Inc. |
Method for diagnosing pancreatic cancer
|
AU2003282679A1
(en)
|
2002-10-04 |
2004-05-04 |
Arena Pharmaceuticals, Inc. |
Hydroxypyrazoles for use against metabolic-related disorders
|
ATE429915T1
(en)
|
2002-10-10 |
2009-05-15 |
Arena Pharm Inc |
5-SUBSTITUTED 2H-PYRAZONE-3-CARBONIC ACID DERIVATIVES AS ANTILIPOLYTIC AGENTS FOR THE TREATMENT OF METABOLIC DISORDERS, SUCH AS DYSLIPIDEMIA
|
JP4103537B2
(en)
|
2002-10-17 |
2008-06-18 |
アステラス製薬株式会社 |
New screening method
|
WO2004039320A2
(en)
|
2002-10-25 |
2004-05-13 |
Collegium Pharmaceutical, Inc. |
STEREOISOMERS OF p-HYDROXY-MILNACIPRAN, AND METHODS OF USE THEREOF
|
US7129239B2
(en)
|
2002-10-28 |
2006-10-31 |
Pfizer Inc. |
Purine compounds and uses thereof
|
AU2003269401A1
(en)
|
2002-11-01 |
2004-05-25 |
Pharmacia & Upjohn Company Llc |
Compounds having both alpha7 nachr agonist and 5ht antagonist activity for treatment of cns diseases
|
US20060263774A1
(en)
|
2002-11-01 |
2006-11-23 |
Genentech, Inc. |
Compositions and methods for the treatment of immune related diseases
|
DE10251244A1
(en)
|
2002-11-04 |
2004-05-19 |
Universität Heidelberg |
Method for detecting compounds with antihyperlipemic activity, useful for identifying therapeutic agents, is based on their interaction with nicotinic acid receptors
|
WO2004041274A1
(en)
|
2002-11-05 |
2004-05-21 |
Arena Pharmaceuticals, Inc. |
Benzotriazoles and methods of prophylaxis or treatment of metabolic-related disorders thereof
|
ATE345342T1
(en)
|
2002-11-11 |
2006-12-15 |
Neurosearch As |
1,4-DIZABICYCLO(3,2,2)NONANE DERIVATIVES, METHOD FOR THEIR PRODUCTION AND THERAPEUTIC USE
|
US7189524B1
(en)
|
2002-11-25 |
2007-03-13 |
Amgen, Inc. |
Receptor ligands and methods of modulating receptors
|
EP1573071A4
(en)
|
2002-11-27 |
2007-02-28 |
Us Gov Health & Human Serv |
Methods for detecting invasion of a cell
|
WO2004052889A1
(en)
|
2002-12-06 |
2004-06-24 |
Pharmacia & Upjohn Company Llc |
Compounds as radioligands for the diagnosis of disease
|
ATE378048T1
(en)
|
2002-12-06 |
2007-11-15 |
The Feinstein Inst Medical Res |
INHIBITION OF INFLAMMATION USING ALPHA-7 RECEPTOR-LINKING CHOLINERGIC AGONISTS
|
OA12968A
(en)
|
2002-12-06 |
2006-10-13 |
Pharmacia & Upjohn Co Llc |
Crystalline fumarate salts of 1-azabicyclo[2.2.2]oct substituted furo[2,3-c]pyridinyl carboxamide and compositions and preparations thereof.
|
US7247628B2
(en)
|
2002-12-12 |
2007-07-24 |
Pfizer, Inc. |
Cannabinoid receptor ligands and uses thereof
|
JP2004198202A
(en)
|
2002-12-17 |
2004-07-15 |
Takeda Chem Ind Ltd |
Novel screening method
|
JP2007524566A
(en)
|
2002-12-20 |
2007-08-30 |
エンカム ファーマシューティカルズ アクティーゼルスカブ |
Methods for modulating the interaction between receptors and ligands
|
US20050059153A1
(en)
*
|
2003-01-22 |
2005-03-17 |
George Frank R. |
Electromagnetic activation of gene expression and cell growth
|
BRPI0406834A
(en)
|
2003-01-22 |
2005-12-27 |
Pharmacia & Upjohn Co Llc |
Treatment of disease with nach alfa-7 total receptor agonists
|
US20050084872A1
(en)
*
|
2003-01-24 |
2005-04-21 |
Lum Pek Y. |
Methods for determining whether an agent possesses a defined biological activity
|
WO2004071394A2
(en)
|
2003-02-13 |
2004-08-26 |
Bayer Healthcare Ag |
Diagnostics and therapeutics for diseases associated with hm74
|
WO2004071378A2
(en)
|
2003-02-17 |
2004-08-26 |
Bayer Healthcare Ag |
Diagnostics and therapeutics for diseases associated with g-protein coupled receptor hm74a (hm74a)
|
WO2004072648A1
(en)
|
2003-02-17 |
2004-08-26 |
Bayer Healthcare Ag |
Diagnostics and therapeutics for diseases associated with g protein-coupled receptor ox2r (ox2r)
|
WO2004076453A1
(en)
|
2003-02-27 |
2004-09-10 |
Neurosearch A/S |
Novel diazabicyclic aryl derivatives
|
JP2007516692A
(en)
*
|
2003-03-07 |
2007-06-28 |
アビアラデックス,インコーポレイティド |
Signs of breast cancer
|
EP1613597B1
(en)
|
2003-03-07 |
2007-11-07 |
Eli Lilly and Company |
6-substituted nicotinamide derivatives as opioid receptor antagonists
|
WO2004080535A2
(en)
|
2003-03-12 |
2004-09-23 |
Millennium Pharmaceuticals, Inc. |
Methods and compositions for treating aids and hiv-related disorders using 9145, 1725, 311, 837, 58305, 156, 14175, 50352, 32678, 5560, 7240, 8865, 12396, 12397, 13644, 19938, 2077, 1735, 1786, 10220, 17822, 33945, 43748, 47161, 81982, or 46777
|
US20070275374A1
(en)
|
2003-03-17 |
2007-11-29 |
Rinat Neuroscience Corp. |
Methods For Idendifying Drug Targets And Modulators Of Neurons and Compositions Comprising The Same
|
WO2004085433A2
(en)
|
2003-03-28 |
2004-10-07 |
Pharmacia & Upjohn Company Llc |
Positive allosteric modulators of the nicotinic acetylcholine receptor
|
CN100387594C
(en)
|
2003-04-03 |
2008-05-14 |
麦克公司 |
Di-aryl substituted pyrazole modulators of metabotropic glutamate receptor-5
|
AU2004225887A1
(en)
|
2003-04-03 |
2004-10-14 |
Merck & Co., Inc. |
4-ring imidazole derivatives as modulators of metabotropic glutamate receptor-5
|
CN100537564C
(en)
|
2003-04-04 |
2009-09-09 |
麦克公司 |
Di-aryl substituted triazole modulators of metabotropic glutamate receptor-5
|
CA2522215A1
(en)
|
2003-04-07 |
2004-10-28 |
Ribonomics, Inc. |
Methods for identifying therapeutic targets involved in glucose and lipid metabolism
|
US7145012B2
(en)
|
2003-04-23 |
2006-12-05 |
Pfizer Inc. |
Cannabinoid receptor ligands and uses thereof
|
US7268133B2
(en)
|
2003-04-23 |
2007-09-11 |
Pfizer, Inc. Patent Department |
Cannabinoid receptor ligands and uses thereof
|
US7141669B2
(en)
*
|
2003-04-23 |
2006-11-28 |
Pfizer Inc. |
Cannabiniod receptor ligands and uses thereof
|
US20040214856A1
(en)
*
|
2003-04-23 |
2004-10-28 |
Pfizer Inc |
Cannabinoid receptor ligands and uses thereof
|
US20050003405A1
(en)
|
2003-04-30 |
2005-01-06 |
Hua-Chien Chen |
Treatment and diagnostics of cancer
|
WO2004099202A1
(en)
|
2003-05-05 |
2004-11-18 |
Pharmacia & Upjohn Company Llc |
Quinuclidines substituted bentodioxine carboxamides for the treatment of neurodegenerative diseases
|
US20040224962A1
(en)
*
|
2003-05-09 |
2004-11-11 |
Pfizer Inc |
Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss
|
AR041089A1
(en)
*
|
2003-05-15 |
2005-05-04 |
Merck & Co Inc |
PROCEDURE AND PHARMACEUTICAL COMPOSITIONS TO TREAT ATEROSCLEROSIS, DYSLIPIDEMIAS AND RELATED AFFECTIONS
|
US20040242644A1
(en)
*
|
2003-05-27 |
2004-12-02 |
Buckley Michael J. |
(IS-5S)-3-(5,6-dichloro-3-pyridinyl-)-3,6-diazabicyclo[3.2.0]heptane is an effective analgesic agent
|
US20040242641A1
(en)
*
|
2003-05-27 |
2004-12-02 |
Buckley Michael J. |
(1S,5S)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane is an effective analgesic agent
|
CA2528162A1
(en)
|
2003-06-04 |
2004-12-16 |
The Government Of The United States As Represented By The Secretary Of T He Department Of Health And Human Services, Centers For Disease Control |
Pni microarray and uses
|
US7232823B2
(en)
*
|
2003-06-09 |
2007-06-19 |
Pfizer, Inc. |
Cannabinoid receptor ligands and uses thereof
|
WO2005007655A1
(en)
*
|
2003-07-21 |
2005-01-27 |
Pfizer Products Inc. |
Nicotine addiction reducing heteroaryl fused azapolycyclic compounds
|
BRPI0412880A
(en)
*
|
2003-07-21 |
2006-10-03 |
Pfizer Prod Inc |
azapolytic compounds fused to aryl
|
US7151097B2
(en)
*
|
2003-11-07 |
2006-12-19 |
Pfizer Inc. |
Bicyclic pyrazolyl and imidazolyl compounds and uses thereof
|
US7816356B2
(en)
*
|
2003-11-14 |
2010-10-19 |
Daniel Yohannes |
Aryl and heteroaryltetrahydrocyclobutapyrroles as nicotinic acetylcholine receptor ligands
|
JP2005198640A
(en)
|
2003-11-25 |
2005-07-28 |
Biomarker Science:Kk |
Method for expressing gene
|
PL1541197T3
(en)
|
2003-12-02 |
2009-10-30 |
Pharmaneuroboost N V |
Use of pipamperone and an SNDRI, SNRI or SSRI for the treatment of mood or anxiety disorders
|
US7309699B2
(en)
*
|
2003-12-22 |
2007-12-18 |
Abbott Laboratories |
3-Quinuclidinyl amino-substituted biaryl derivatives
|
EP1718292A1
(en)
*
|
2004-02-20 |
2006-11-08 |
Aventis Pharmaceuticals Inc. |
Furosemide derivatives as modulators of hm74 and their use for the treatment of inflammation disorders
|
CN1929833A
(en)
*
|
2004-02-20 |
2007-03-14 |
安万特药物公司 |
Oxydecahydronaphthalene modulators of HM74
|
JP2005253442A
(en)
|
2004-03-09 |
2005-09-22 |
Hitachi Medical Corp |
Gene group having expression profile different between human dental pulp stem cell and mesenchymal stem cell
|
WO2006009629A2
(en)
*
|
2004-06-10 |
2006-01-26 |
New York University |
Methods and agents for maintaining muscle mass and for preventing muscle atrophy and biomarkers for monitoring same
|
WO2006023312A2
(en)
*
|
2004-08-20 |
2006-03-02 |
Carl Deirmengian |
Diagnostic assay for source of inflammation
|
US20060154275A1
(en)
*
|
2004-12-02 |
2006-07-13 |
The Board Of Trustees Of The Leland Stanford Junior University |
Regulated genes in cervical cancer
|
EP1677113A1
(en)
|
2004-12-29 |
2006-07-05 |
Max-Delbrück-Centrum für Molekulare Medizin (MDC) |
Method for the identification of protein-protein interactions in disease related protein networks
|
AU2006259137B2
(en)
*
|
2005-06-14 |
2010-04-01 |
F. Hoffmann-La Roche Ag |
Anthranilic acid derivatives
|
WO2007002557A1
(en)
*
|
2005-06-28 |
2007-01-04 |
Merck & Co., Inc. |
Niacin receptor agonists, compositions containing such compounds and methods of treatment
|